Portfolio company
Cellemedy
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
The company develops next-generation protein therapeutics and immuno-oncology drugs for patients suffering from cancer.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Captain T Cell
The company develops cell therapies for cancer patients to treat solid tumours.
CellmAbs
This biotech company develops monoclonal antibodies and adoptive cell therapies to treat oncology patients with solid tumours.
Cold Start Therapeutics
This company develops multimeric fusion proteins using machine learning to target cancer cells and engage immune cells for patients with oncological diseases.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
EdiTy Therapeutics
This company develops immune cell delivery platforms to transport therapeutic proteins into diseased cells for patients with cancer and genetic disorders.
Nectin Therapeutics
This company develops novel immunotherapeutic antibodies and antibody-drug conjugates for patients with solid and haematological cancers.
Callio Therapeutics
The company develops multi-payload antibody-drug conjugates to treat cancer patients.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.